Journal of Clinical Oncology, Vol 13, 165-176, Copyright © 1995 by American Society of Clinical Oncology

ARTICLES

Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem

AG Freifeld, T Walsh, D Marshall, J Gress, SM Steinberg, J Hathorn, M Rubin, P Jarosinski, V Gill and RC Young
Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

PURPOSE: To compare the efficacy of ceftazidime and imipenem monotherapy for fever and neutropenia, and to determine whether fewer antimicrobial modifications (additions or changes) are required by the broader-spectrum agent, imipenem. PATIENTS AND METHODS: Adult and pediatric patients undergoing chemotherapy for solid tumors, leukemias, or lymphomas were randomized to receive open-label ceftazidime or imipenem on presentation with fever and neutropenia. Success with or without modifications of the initial antibiotic was defined as survival through neutropenia; failure was death due to infection. Comparisons were based on numbers of modifications made to each monotherapy during the course of neutropenia, in patients stratified as having unexplained fever or a documented infection. RESULTS: Among 204 ceftazidime and 195 imipenem recipients, the overall success rate with or without modification was more than 98%, regardless of initial antibiotic regimen. Modifications occurred in half of all episodes, primarily in patients with documented infections on either monotherapy. Antianaerobic agents were more frequently added to ceftazidime (P < .001), but addition of other antibiotics, including vancomycin and aminoglycosides, was similar between the two monotherapy groups. Imipenem therapy was associated with significantly greater toxicity, manifested by Clostridium difficile-associated diarrhea and by nausea and vomiting, which required discontinuation of imipenem in 10% of recipients. CONCLUSION: Ceftazidime and imipenem are both effective in the management of fever and chemotherapy-related neutropenia, provided that modifications are made in response to clinical and microbiologic data that emerge during the course of neutropenia. Imipenem, despite its broader antimicrobial spectrum, does not significantly decrease the overall need for antibiotic modifications and is more often complicated by gastrointestinal toxicity.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. A. Pizzo Where do we go from here? J. Antimicrob. Chemother., May 1, 2009; 63(suppl_1): i16 - i17. [Abstract] [Full Text] [PDF]

				M. Paul, D. Yahav, A. Fraser, and L. Leibovici Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials J. Antimicrob. Chemother., February 1, 2006; 57(2): 176 - 189. [Abstract] [Full Text] [PDF]

				W. G. Nichols Management of Infectious Complications in the Hematopoietic Stem Cell Transplant Recipient J Intensive Care Med, November 1, 2003; 18(6): 295 - 312. [Abstract] [PDF]

				G. Fleischhack, C. Hartmann, A. Simon, B. Wulff, W. Havers, G. Marklein, C. Hasan, and U. Bode Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer J. Antimicrob. Chemother., June 1, 2001; 47(6): 841 - 853. [Abstract] [Full Text] [PDF]

				R. Feld, B. DePauw, S. Berman, A. Keating, and W. Ho Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial J. Clin. Oncol., November 1, 2000; 18(21): 3690 - 3698. [Abstract] [Full Text] [PDF]

				L. S. Elting, E. B. Rubenstein, K. Rolston, S. B. Cantor, C. G. Martin, D. Kurtin, S. Rodriguez, T. Lam, K. Kanesan, and G. Bodey Time to Clinical Response: An Outcome of Antibiotic Therapy of Febrile Neutropenia With Implications for Quality and Cost of Care J. Clin. Oncol., November 1, 2000; 18(21): 3699 - 3706. [Abstract] [Full Text] [PDF]

				P. A. Pizzo Fever in Immunocompromised Patients N. Engl. J. Med., September 16, 1999; 341(12): 893 - 900. [Full Text] [PDF]

				A. Freifeld, D. Marchigiani, T. Walsh, S. Chanock, L. Lewis, J. Hiemenz, S. Hiemenz, J. E. Hicks, V. Gill, S. M. Steinberg, et al. A Double-Blind Comparison of Empirical Oral and Intravenous Antibiotic Therapy for Low-Risk Febrile Patients with Neutropenia during Cancer Chemotherapy N. Engl. J. Med., July 29, 1999; 341(5): 305 - 311. [Abstract] [Full Text] [PDF]